ChemDiv has been a pioneer in discovery libraries since 1991. Its first diverse heterocyclic compounds collection was compiled from academic lab sources from all over the world, and ChemDiv subsequently successfully launched its own large-scale library synthesis program.
ChemDiv is now the recognized global leader in discovery chemistry with the industry's largest, most diverse, and most pharmacologically-relevant commercial collection of individually crafted, lead-like, drug-like small molecules and building blocks.
During the course of our synthetic and screening endeavors, we have identified a range of approaches to both diverse and highly specialized (focused) compound selections. These compound libraries have been extensively validated in our in-house biological assays as well as in the laboratories of over 200 external partners including Pharma, Biotech, Academia and Screening Centers in the U.S., Europe and Japan.
Our computational, structural biology, synthetic and medicinal chemistry team follow current trends in modern structure-based discovery chemistry to add novel diverse and targeted compounds. The latter selections are aimed at tackling multiple targets, protein domains, pathways, cellular processes, etc. Representative examples of these biased compound libraries include modulators of numerous protein-protein interactions, stem cell differentiation, apoptosis, proteasome cascade including diverse ligases, autophagy, epigenetics machinery, cell cycle including quiescent cancer cells, motor proteins, mitochondrial homeostasis and cell energetic, viral targets, bacterial genome, protein folding machinery including scaffolding proteins and chaperones and many others. We have also assembled library screening sets for agrochemical, cosmetics and food industries reflective of the Generally Recognized As Safe (GRAS) concepts.
Our compound libraries observe modern definitions of lead-like properties. Our multidisciplinary team has put forth specialized small molecule libraries focused on chemical diversity-, soluble diversity-, blood-brain permeability, rigid topology (spiro-heterocycles and macrolide analogues), Fsp3 character, medium- and large-size rings (macrocycles) and other criteria.
Needless to say, all libraries are regularly updated at the rate of 30K new screening compounds per year with our novel, IP-defined compounds resulting from the internal development. Our highly diverse molecules are produced using traditional synthetic approaches with yields of up to 100-150 mg per screening compound and average purity greater than 90% as determined by both NMR and LCMS analyses.